T. Nakamura, H. Takano, K. Umetani, K. Kawabata, J. E. Obata, Y. Kitta, et al., “Remnant Lipoproteinemia Is a Risk Factor for Endothelial Vasomotor Dysfunction and Coronary Artery Disease in Metabolic Syndrome,” Atherosclerosis, Vol. 181, No. 2, 2005, pp. 321-327. doi:10.1016/j.atherosclerosis.2005.01.012

has been cited by the following article:

• TITLE: Combination Lipid Therapy on Lipid Profiles in Patients with Impaired Glucose Tolerance

  AUTHORS: Hiroaki Kawano, Yasuhiro Nagayoshi, Hisao Ogawa, Yoshihiro Kinoshita

  KEYWORDS: Statins; Fibrates; Dyslipidemia

  JOURNAL NAME: International Journal of Clinical Medicine, Vol.4 No.3, March 22, 2013

  ABSTRACT: Objective: This study compared the effects of combination statin and fibrate therapy with either statin or fibrate monotherapy on lipid profiles in patients with impaired glucose tolerance (IGT) and a high risk for cardiovascular disease. Methods & Patients: Forty-five patients with IGT and dyslipidemia (men 25, women 20, mean age 61.7 ± 2.4 yrs) were assigned randomly to the 3 treatment groups for a 6-month period. Results: After 6 months of treatment, low density lipoprotein levels decreased in every group, especially the statin and statin + fibrate groups. Triglyceride levels also decreased in all three groups, especially the fibrate and statin + fibrate groups. High density lipoprotein cholesterol and fasting blood glucose levels did not change in any group. The levels of remnant like cholesterol particles decreased in the fibrate and statin + fibrate groups. There was no change during the study in the levels of creatine phosphokinase, lactate dehydrogenase, or creatinine. Conclusion: Combination statin and fibrate therapy results in greater improvement in lipid profiles than monotherapy with either drug. No marked adverse effects were observed with combination therapy during the study.